NUZYRA® (omadacycline) BILLING AND CODING GUIDE

Paratek Pharmaceuticals, Inc. is pleased to provide this billing and coding resource to help healthcare providers appropriately bill for NUZYRA and its administration. This resource contains relevant information and guidance for claims submitted to commercial/private payers and government-sponsored insurance plans, including Medicare and Medicaid.

This Billing and Coding Guide is intended to provide general information only, and Paratek Pharmaceuticals, Inc. cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payer, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims. For additional information, customers should consult with their payers for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the healthcare provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.

# Questions? Call NUZYRA Central<sup>®</sup> Support Services at 1-877-4-NUZYRA (1-877-468-9972),

Mon-Fri, 8 AM to 8 PM ET to speak with a representative.





Vial and tablets not shown at actual size.



### INDICATIONS AND IMPORTANT SAFETY INFORMATION

### INDICATIONS AND USAGE

NUZYRA® (omadacycline) is a tetracycline-class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms:

#### **Community-Acquired Bacterial Pneumonia (CABP) caused by**

**the following:** *Streptococcus pneumoniae*, *Staphylococcus aureus* (methicillin-susceptible isolates), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.

### Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

caused by the following: Staphylococcus aureus (methicillinsusceptible and -resistant isolates), Staphylococcus lugdunensis, Streptococcus pyogenes, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Enterococcus faecalis, Enterobacter cloacae, and Klebsiella pneumoniae.

### USAGE

To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

### **IMPORTANT SAFETY INFORMATION** CONTRAINDICATIONS

NUZYRA is contraindicated in patients with known hypersensitivity to omadacycline or tetracycline-class antibacterial drugs, or to any of the excipients.

### WARNINGS AND PRECAUTIONS

Mortality imbalance was observed in the CABP clinical trial with eight deaths (2%) occurring in patients treated with NUZYRA compared to four deaths (1%) in patients treated with moxifloxacin. The cause of the mortality imbalance has not been established. All deaths, in both treatment arms, occurred in patients >65 years of age; most patients had multiple comorbidities. The causes of death varied and included worsening and/or complications of infection and underlying conditions. Closely monitor clinical response to therapy in CABP patients, particularly in those at higher risk for mortality.

The use of NUZYRA during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.

The use of NUZYRA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth.

Hypersensitivity reactions have been reported with NUZYRA. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with other tetracycline-class antibacterial drugs. NUZYRA is structurally similar to other tetracycline-class antibacterial drugs and is contraindicated in patients with known hypersensitivity to tetracycline-class antibacterial drugs. Discontinue NUZYRA if an allergic reaction occurs.

Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.

NUZYRA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions, including photosensitivity, fixed drug eruption, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests). have been reported for other tetracycline-class antibacterial drugs, and may occur with NUZYRA. Discontinue NUZYRA if any of these adverse reactions are suspected.

Prescribing NUZYRA in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

### **ADVERSE REACTIONS**

The most common adverse reactions (incidence  $\geq 2\%$ ) are nausea, vomiting, infusion site reactions, alanine aminotransferase increased. aspartate aminotransferase increased, gamma-glutamyl transferase increased, hypertension, headache, diarrhea, insomnia, and constipation.

### DRUG INTERACTIONS

Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage while taking NUZYRA.

Absorption of tetracyclines, including NUZYRA is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron containing preparations.

### **USE IN SPECIFIC POPULATIONS**

Lactation: Breastfeeding is not recommended during treatment with NUZYRA.

Please see full Prescribing Information in pocket.



### 2 BIOEQUIVALENT FORMULATIONS, ONCE-DAILY DOSING **IN ABSSSI AND CABP1\***

NUZYRA dosage and administration

### DOSAGE OF NUZYRA IN ADULT PATIENTS WITH CABP OR ABSSSI – TREATMENT DURATION: 7-14 DAYS

INFECTION	LOADING DOSES	MAINTENANCE DOSE
САВР	Day 1: 200 mg by intravenous infusion over 60 minutes <b>OR</b> 100 mg by intravenous infusion over 30 minutes twice	100 mg by intravenous infusion over 30 minutes once daily <b>OR</b> 300 mg orally once daily
CABP NUZYRA tablets only)	Day 1: 300 mg orally <u>twice</u>	300 mg orally once daily
ABSSSI	Day 1: 200 mg by intravenous infusion over 60 minutes <b>OR</b>	100 mg by intravenous infusion over 30 minutes once daily ————————————————— 300 mg orally once daily
ABSSSI NUZYRA tablets only)	Days 1 and 2: 450 mg orally once daily	300 mg orally once daily

\*For treatment of CABP, the oral loading dose is 300 mg twice on Day 1.1

### **IMPORTANT CONSIDERATIONS** WHEN PRESCRIBING NU7YRA<sup>1</sup>

FOR NUZYRA IV Do NOT administer with any solution containing

- multivalent cations (eg, calcium and magnesium) through the same intravenous line
- The compatibility of NUZYRA with other drugs and infusion solutions other than 5% Dextrose Injection, USP, or 0.9% Sodium Chloride Injection, USP, has not been established

### FOR NUZYRA ORAL

- · Fast for at least 4 hours and then take with water - NUZYRA can be taken at bedtime or upon waking
- Do not eat or drink (except water) for 2 hours after dosing

· Alternative IV loading dose: 100 mg over 30 minutes twice on Day 1



Vial is not actual size

· No dairy products, antacids, or multivitamins for 4 hours after dosing

 Patients taking anticoagulant therapy may require downward adjustment of their anticoagulant dosage while taking NUZYRA



Tablets are not actual size

### ICD-10-CM DIAGNOSTIC CODING FOR NUZYRA

ICD-10-CM codes are used by physicians to report a patient's diagnosis. The following may apply to conditions covered within the approved Prescribing Information for NUZYRA. Paratek Pharmaceuticals, Inc. does not guarantee payment with respect to any particular code and we do not intend through this information to suggest a prescribing decision for any patient. Those decisions are within the prescriber's individual judgment. Below is a list of codes that may be helpful.

#### Acute Bacterial Skin And Skin Structure Infections (ABSSSI)<sup>2</sup>

ICD-10-CM CODE	DESCRIPTION	
A46	Erysipelas	
A49.0	Staphylococcal infection, unspecified site	
A49.01	Methicillin-susceptible <i>Staphylococcus aureus</i> infection, unspecified site	
A49.02	Methicillin-resistant <i>Staphylococcus aureus</i> infection, unspecified site	
A49.1	Streptococcal infection, unspecified site	
A49.9	Bacterial infection, unspecified	
B95.0	<i>Streptococcus</i> group A as the cause of diseases classified elsewhere	
B95.2	Enterococcus as the cause of diseases classified elsewhere	
B95.4	Other <i>Streptococcus</i> as the cause of diseases classified elsewhere	
B95.5	Unspecified <i>Streptococcus</i> as the cause of diseases classified elsewhere	
B95.61	Methicillin-susceptible <i>Staphylococcus aureus</i> infection as the cause of diseases classified elsewhere	
B95.62	Methicillin-resistant <i>Staphylococcus aureus</i> infection as the cause of diseases classified elsewhere	
B95.8	Unspecified <i>Staphylococcus</i> as the cause of diseases classified elsewhere	
H60.00-H60.03	Abscess of external ear	
H60.10-H60.13	Cellulitis of external ear	
J34.0	Abscess, furuncle and carbuncle of nose	
L02.01-L02.03	Cutaneous abscess, furuncle and carbuncle of face	
L02.11-L02.13	Cutaneous abscess, furuncle and carbuncle of neck	
L02.211-L02.239	Cutaneous abscess, furuncle and carbuncle of abdominal wall	
L02.31-L02.33	Cutaneous abscess, furuncle and carbuncle of buttock	
L02.411-L02.439	Cutaneous abscess, furuncle and carbuncle of limb	
L02.511-L02.539	Cutaneous abscess, furuncle and carbuncle of hand	
L02.611-L02.639	Cutaneous abscess, furuncle and carbuncle of foot	
L02.811-L02.818	Cutaneous abscess, furuncle and carbuncle of other sites	
L02.91-L02.93	Cutaneous abscess, furuncle and carbuncle, unspecified	
L03.011-L03.019	Cellulitis of finger	
L03.031-L03.039	Cellulitis of toe	
L03.1-L03.119	Cellulitis of other parts of limb	
L03.211	Cellulitis of face	
L03.221	Cellulitis of neck	
L03.311-L03.319	Cellulitis of trunk	
L03.811-L03.818	Cellulitis of other sites	
L03.90	Cellulitis, unspecified	
L08-L08.9	Other local infections of skin and subcutaneous tissue	
N61.1	Abscess of the breast and nipple	

#### Community-Acquired Bacterial Pneumonia (CABP)<sup>2</sup>

ICD-10-CM CODE	DESCRIPTION
A49.0	Staphylococcal infection, unspecified site
A49.01	Methicillin-susceptible Staphylococcus aureus infection, unspecified site
A49.1	Streptococcal infection, unspecified site
A49.3	Mycoplasma infection, unspecified site
B95.0	Streptococcus group A as the cause of diseases classified elsewhere
B95.3	Streptococcus pneumoniae as the cause of diseases classified elsewhere
B95.4	Other <i>Streptococcus</i> as the cause of diseases classified elsewhere
B95.5	Unspecified <i>Streptococcus</i> as the cause of diseases classified elsewhere
B96.0	Mycoplasma pneumoniae as the cause of diseases classified elsewhere
B96.1	Klebsiella pneumoniae as the cause of diseases classified elsewhere
B96.3	Haemophilus influenzae as the cause of diseases classified elsewhere
J13	Pneumonia due to Streptococcus pneumoniae
J14	Pneumonia due to Haemophilus influenzae
J15	Bacterial pneumonia, not elsewhere classified
J15.7	Pneumonia due to Mycoplasma pneumoniae
J16.0	Chlamydial pneumonia
J18.0	Bronchopneumonia, unspecified organism
J18.1	Lobar pneumonia, unspecified organism
J18.8	Other pneumonia, unspecified organism
J18.9	Pneumonia unspecified organism

 $\label{eq:constraint} \ensuremath{\mathsf{ICD-10-CM}}\xspace = \ensuremath{\mathsf{ICD-10-CM}}\xspace = \ensuremath{\mathsf{ICm}}\xspace = \ensurema$ 



### **HEALTHCARE COMMON PROCEDURE** CODING SYSTEM (HCPCS) J-CODE

Below are relevant codes related to submitting claims for NUZYRA. Effective 10/1/19, the permanent HCPCS J-Code J0121 may allow for reimbursement of NUZYRA IV. A sample HCPCS form is available in the back pocket of this guide.

HCPCS CODE	
J0121	

\*Based on lowest divisible dose per infusion (1 mg/mL).

Beginning January 1, 2023, Centers for the Medicare & Medicaid Services (CMS) will require all outpatient providers to include the modifier "JZ" on all Medicare claim forms for NUZYRA when the entire vial is administered to the patient and none was discarded. If less than a full dose of NUZYRA IV is administered to a patient for any reason and, therefore, there is a discarded amount, providers should bill for the amount administered to the patient on a single claim line with the JZ modifier and bill for the discarded amount on a separate claim line with the modifier "JW." Beginning October 1, 2023, claim forms that do not include the JZ modifier may be returned to providers by local Medicare Administrative Contractors (MACs) for reprocessing.

### CURRENT PROCEDURAL TERMINOLOGY (CPT®) CODES

Created by the AMA, these codes indicate professional medical procedures and services.

CPT CODE	
96365	IV infusion for t
96366	IV infusion for th
99601	Но
99602	Each ac

AMA=American Medical Association.

### NUZYRA NDC CODES

#### NUZYRA packaging with National Drug Codes (NDCs)

NUZYRA PACKAGING	NDC
100 mg individual vial Carton containing 10 vials	71715-001-02
Blister package of 6 Blister package of 30	71715-002-21 71715-002-27

Some payers require physicians to report 11-digit NDCs when listing a drug on a claim form. To do this, add a zero to the middle section.

NUZYRA 10-DIGIT NDC	NUZYRA 11-DIGIT I WITH LEADING ZE
71715-001-02	71715-0001-02

Please see Indications, Usage, and Important Safety Information on page 2 and full Prescribing Information in pocket.



#### DESCRIPTION

therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour

herapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour

lome infusion/specialty drug administration, per visit (up to 2 hours)

additional hour (list separately in addition to code for primary procedure)



## **SAMPLE** CLAIM FORMS


#### CMS-1500 Claim Form – Physician Office

The Form CMS-1500 is the basic form prescribed by CMS for the Medicare and Medicaid programs for claims from suppliers and non-institutional providers that qualify for a waiver from the Administrative Simplification Compliance Act (ASCA) requirement for electronic submission of claims. It has also been adopted by the TRICARE Program. For detailed guidance on completing the CMS-1500 items, please see the Medicare Claims Processing Manual, Pub. 100-04, Chapter 26, available at: https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c26.pdf

	1500 HEALTH INSURANCE CLAIM F			CARRIER
	APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE			- CAF
	PICA			
	1. MEDICARE MEDICAID TRICARE (Medicare #) (Medicaid #) (Sponsor's SSN)	CHAMPVA GROUP FECA OTHE HEALTH PLAN BLK LUNG ( <i>Member ID#</i> ) ( <i>SSN or ID</i> ) ( <i>ID</i> ) ( <i>ID</i> )	ER 1a. INSURED'S I.D. NUMBER (For Program	in Item 1)
	2. PATIENT'S NAME (Last Name, First Name, Middle Initial	3. PATIENT'S BIRTH DATE SEX	4. INSURED'S NAME (Last Name, First Name, Middle Initial)	
	5. PATIENT'S ADDRESS (No., Street)	6. PATIENT RELATIONSHIP TO INSURED	7. INSURED'S ADDRESS (No., Street)	
	CITY	Self Spouse Child Other STATE 8. PATIENT STATUS	CITY	STATE Z
	ZIP CODE TELEPHONE (Include A	ea Code) Single Married Other	ZIP CODE TELEPHONE (Include Area 0	
	( )	Employed Full-Time Part-Time Student		
	9. OTHER INSURED'S NAME (Last Name, First Name, Mid	dle Initial) 10. IS PATIENT'S CONDITION RELATED TO:	11. INSURED'S POLICY GROUP OR FECA NUMBER	
	a. OTHER INSURED'S POLICY OR GROUP NUMBER	a. EMPLOYMENT? (Current or Previous)	a. INSURED'S DATE OF BIRTH SEX	F SI
	b. OTHER INSURED'S DATE OF BIRTH SEX	b. AUTO ACCIDENT? PLACE (State		
	C. EMPLOYER'S NAME OR SCHOOL NAME	c. OTHER ACCIDENT?	C. INSURANCE PLAN NAME OR PROGRAM NAME	
	d. INSURANCE PLAN NAME OR PROGRAM NAME	YES NO	d. IS THERE ANOTHER HEAI TH BENEFIT PLAN?	
			YES NO If yes, return to and complete it	tem 9 a-d.
OX 21:	READ BACK OF FORM BEFOR PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE to process this claim. I also request payment of government	COMPLETING & SIGNING THIS FORM. I authorize the release of any medical or other information necessary t benefits either to myself or to the party who accepts assignment	<ol> <li>INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I a payment of medical benefits to the undersigned physician or services described below.</li> </ol>	uthorize supplier for
iter the	below.	DATE	SIGNED	$\downarrow$
opropriate	4. DATE OF CURRENT: MM   DD   YY INJURY (Accident) OR		IS. 16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCU	IPATIQN ▲
D-10-CM	7. NAME OF REFERRING PROVIDER OR OTHER SOUR		FROM TO 18. HOSPITALIZATION DATES RELATED TO CURRENT SERV MM DD YY MM DD	
agnosis code.	). RESERVED FOR LOCAL USE	17b. NPI	FROM 1 TO 1 20. OUTSIDE LAB? \$ CHARGES	
			YES NO	BOX 24I & J:
	21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY (R	3.	22. MEDICAID RESUBMISSION CODE ORIGINAL REF. NO.	National Provider
		4	23. PRIOR AUTHORIZATION NUMBER	Identifier.
	2 24. A. DATE(S) OF SERVICE B. C From To PLACE OF	D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) DIAGNOS	F. G. H. I	
_	MM DD YY MM DD YY SERVICE EM	G CPT/HCPCS   MODIFIER POINTER	R \$CHARGES UNITS Plan QUAL. PROVIE	
<b>30X 24D:</b>			NPI	Ie
nter the appro	opriate HCPCS and CPT codes.		<b>BOX 24D:</b>	
	' 1 [Injection, omadacycline,		Include the mod	lifier "JZ" on all
	/ infusion for therapy,		Medicare claim	forms for NUZYRA
	diagnosis; initial, up to 1 hour]		when the entire	vial is administered.
her administ	tration codes may			
e appropriate		. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT?	28. TOTAL CHARGE 29. AMOUNT PAID 30. BAL	
		SERVICE FACILITY LOCATION INFORMATION	\$   \$   \$ 33. BILLING PROVIDER INFO & PH # ( )	
	INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse			
	apply to this bill and are made a part thereof.)			
	apply to this bill and are made a part thereof.)			

#### CMS-1450 (UB-04) Claim Form – Institutional or Hospital Billing

Note: For certain payers, providers must also include the NDC number in Box 43. Specific instructions for formatting this field are available in the Medicare Claims Processing Manual, Chapter 25, available at: http://www.cms.hhs.gov/manuals/downloads/clm104c25.pdf





NUZYRA® (omadacycline) <sup>100 mg for injection</sup> <sup>150 mg tablets</sup>




With the NUZYRA Copay Program, the majority of eligible commercially-insured patients may pay as little as [\$0].\*

\*Terms and conditions apply.

Insurance coverage and reimbursement for NUZYRA are not guaranteed. Coverage and reimbursement depend on an individual patient's insurance plan. We recommend that you contact the insurance provider to verify NUZYRA coverage and reimbursement.

### **NUZYRA CENTRAL® IS A RESOURCE THROUGHOUT THE PATIENT JOURNEY**

### NUZYRA Central® provides patient support and resources



US-MKA-0197-01 04/25